Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Keunchil Park"'
Autor:
Myung-Ju Ahn, Yoon-La Choi, Se-Hoon Lee, Jong-Mu Sun, Youjin Kim, Boram Lee, Keunchil Park, Joon Ho Shim, Woong-Yang Park, Jin Seok Ahn
Publikováno v:
Journal of Thoracic Oncology. 14:193-202
EGFR-mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor (TKI) treatment. Because co-occurring genomic alterations might describe different biological subsets of patients with this cancer, exploring co-occurring genomic alterations th
Autor:
Jinhyun Cho, Haa Na Song, Kwai Han Yoo, Myung-Ju Ahn, Sung Hee Lim, Woong-Yang Park, Hae Su Kim, Jin Seok Ahn, Se-Hoon Lee, Ki Sun Jung, Keunchil Park, Jong Mu Sun, Ji Yun Lee, Yoon-La Choi
Publikováno v:
Journal of Thoracic Oncology. 11(4):e45-e47
T790M mutation is most common resistant mechanism to epidermal growth factor receptor gene (EGFR) tyrosin kinase inhibitor (TKI). Several third-generation EGFR-mutant selective TKI, such as AZD9291 (AstraZeneca), Rociletinib (Clovis), or HM61713 (Han
Autor:
Yi-Long Wu, Li Zhang, Keunchil Park, Reury Perng Perng, Joseph S. K. Au, Caicun Zhou, Tony Mok
Publikováno v:
Journal of Thoracic Oncology. 5(10):1609-1615
Introduction:Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that significantly increases survival for patients with previously treated advanced non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase i
Autor:
Jeeyun Lee, Yun-Hee Park, Jin-Seok Ahn, Argyrios Ziogas, Myung-Ju Ahn, Keunchil Park, Sai-Hong Ignatius Ou, Jason A. Zell
Publikováno v:
Journal of Thoracic Oncology. 5(8):1185-1196
BackgroundWe have previously demonstrated, using a regional California Cancer Registry database, that Asian ethnicity is an independent favorable prognostic factor for overall survival (OS) in non-small cell lung cancer (NSCLC).MethodsRetrospective p
Autor:
Sang We Kim, Byeong Bae Park, Heung Tae Kim, Sang Won Shin, Jong Seog Lee, Chang Hak Sohn, Jin Hyuck Choi, Myung-Ju Ahn, Se Hoon Park, Jin Hyung Kang, Keunchil Park, Ji Eun Uhm, Jin Seok Ahn, Jae Yong Cho, Jeeyun Lee, Hong Suk Song
Publikováno v:
Journal of Thoracic Oncology. 4:1136-1143
Background Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good tolerability in non-small cell lung cancer (NSCLC). In particular, higher re
Autor:
Haesu Kim, Jin Seok Ahn, Myung-Ju Ahn, Min-Young Lee, Bo Mi Ku, Keunchil Park, Jong Mu Sun, Ji Yun Lee, Sung-min Kim, Sung Hee Lim, Hyun Ae Jung, M. Kim
Publikováno v:
Journal of Thoracic Oncology. (6):903-909
Introduction A germline BIM deletion polymorphism has been proposed to predict poor treatment response to certain kinase inhibitors. The purpose of this study was to explore whether the BIM deletion polymorphism predicts treatment efficacy of epiderm
Publikováno v:
Journal of Thoracic Oncology. (4):506-511
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and prolonged progression-free survival (PFS) in patients harboring an acti
Autor:
Masatoshi Sugeno, Shinichi Toyooka, Jin-Haeng Chung, Keunchil Park, Van Khanh Tran, Nicola Normanno, Teh Ying Chou, Ahmad Utomo, Jabed Iqbal, Tony Mok, Chun-Ming Tsai, Shanop Shuangshoti, Geon Kook Lee, Li Zhang, Zhiyong Liang, Yasushi Yatabe, Xiang Du, Ma. Luisa Enriquez, Keith M. Kerr, Paul Waring, Pathmanathan Rajadurai, Marianne Ratcliffe, Yohji Itoh, Koichi Hagiwara, Rose McCormack
Publikováno v:
Journal of Thoracic Oncology
Introduction The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non–small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been ado